bariatric surgery News
-
Ezisurg Medical presented at the European Bariatric Endoscopic Surgery Congress
On 23-24th September, 2021, the annual European Bariatric Endoscopic Surgery Trends (BEST) was successfully held in Montpellier, France. The BEST congress adopted a unique mode of online and offline access, bringing global experts and scholars together to discuss the cutting-edge progress in the field of bariatric surgery. Ezisurg Medical was honored to become the platinum partner of BEST, and ...
-
ReShape Medical, Inc. Completes $38 Million Series D Financing
ReShape Medical® today announced that it has completed a Series D financing of $38 million led by HealthCor Partners Management, L.P. with participation from Endeavour Vision SA and existing investors, SV Life Sciences, New Leaf Venture Partners, U.S. Venture Partners and Venture Investors. The announcement follows the recent approval of the ReShape™ Integrated Dual Balloon System, a ...
-
ReShape Lifesciences Receives USPTO Issue Notification for Patent Covering its ReShape Vest
ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today announces that the United States Patent and Trademark Office (“USPTO”) has issued an Issue Notification for U.S. Patent Number 10010441 entitled “Gastric Restriction Device for Treating Obesity,” which covers a patent application ...
-
Altimmune Announces Initiation Of 48-Week Phase 2 MOMENTUM Trial Of Pemvidutide In Obesity
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first subject in the 48-week Phase 2 MOMENTUM trial evaluating the safety and efficacy of pemvidutide1 in subjects with obesity or overweight. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and ...
-
GI Dynamics Announces Final Data from the ENDO Trial, a Multicenter Study Demonstrating the Potential Use of EndoBarrier to Treat Type II Diabetes and Obesity.
Initial results show the duodenal jejunal bypass liner (DJBL) technology met overall glycemic control efficacy and SAE related device removal safety endpoints Findings Presented at DDW 2022 BOSTON – June 15, 2022 – GI Dynamics, a medical device company that is developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and obesity, announced results from a ...
-
Fractyl Health Provides Initial Clinical Update on Open-Label REVITA-T2Di
REVITA-T2Di is an open-label cohort evaluating Revita DMR® in patients with insulin-treated type 2 diabetes – Revita® in the T2Di cohort has been observed to be well tolerated and all patients previously on long-acting insulin have discontinued insulin therapy in the initial follow-up period – Regular updates on the extended follow-up of the REVITA-T2Di cohort in ...
-
How virtually `scrubbing in` could help surgeons hone their skills
There are a slew of digital health startups looking to change the surgical space to make it more connected, from Hillrom's surgical communication tool to Activ Surgical’s solution that gives surgeons real-time intraoperative visual data. London-based virtual surgery platform Proximie is looking to tackle surgical connectivity challenges with its augmented reality, machine learning and ...
-
ReShape Lifesciences Receives FDA 510(k) Clearance for the GIBI HD Calibration Tubes for use in Gastric and Bariatric Procedures
New Calibration Tubes, in Three Sizes, Will Simplify Gastric and Bariatric Procedures Including Laparoscopic Sleeve Gastrectomy, Gastric Bypass and Gastric Banding Company to Introduce Product at IFSO 2022 World Congress in August; Sales to Commence in September ReShape Lifesciences (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced ...
-
ReShape Lifesciences Technologies to be Featured at Minimally Invasive Surgery Symposium
ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, announced today that the Company and its products will be discussed during the Metabolic and Bariatric Sessions of the Minimally Invasive Surgery Symposium (MISS) taking place in Las Vegas from March 6-9, 2018. Details of the presentations are as follows: Friday, ...
-
Activ Surgical Completes First In-Human Procedures to Demonstrate Impact of its Surgical Intelligence and Sensing Platform
BOSTON — November 3, 2021 — Activ Surgical™, a digital surgery pioneer, today announced the completion of its first in-human surgery clinical trial utilizing the company’s technology-as-a-service bundle—the ActivInsights™ augment reality (AR)-based software suite and the ActivSight™ imaging module. Procedures for the study at The University of Texas ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you